Health and fertility in World Health Organization group 2 anovulatory women
Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation. Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presente...
Gespeichert in:
| Veröffentlicht in: | Human reproduction update 2012-09, Vol.18 (5), p.586-599 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 599 |
|---|---|
| container_issue | 5 |
| container_start_page | 586 |
| container_title | Human reproduction update |
| container_volume | 18 |
| creator | Baird, D. T. Balen, A. Escobar-Morreale, H. F. Evers, J. L. H. Fauser, B. C. J. M. Franks, S. Glasier, A. Homburg, R. La Vecchia, C. Devroey, P. Diedrich, K. Fraser, L. Gianaroli, L. Liebaers, I. Sunde, A. Tapanainen, J. S. Tarlatzis, B. Van Steirteghem, A. Veiga, A. Crosignani, P. G. |
| description | Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation.
Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion.
Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results.
Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health. |
| doi_str_mv | 10.1093/humupd/dms019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1030349656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1030349656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-eeaeb52298549808dd77d1da995f3cb2d955595d4f6995436148f4fc054c94fd3</originalsourceid><addsrcrecordid>eNo9kDtPwzAURi0EoqUwsiKPLKF2_Eg8oopSRKUuIMbIje02yImDH6Dy6wlKYbpX9zv3Gw4A1xjdYSTIfJ_a1Ku5agPC4gRMMeUoywkXp8NOGMtoUfIJuAjhHSHMcVmcg0mec4xxwabgeaWljXsoOwWN9rGxTTzApoNvzlsFj-nG72TXfMvYuA7uvEs9zIcX95msjM4f4JdrdXcJzoy0QV8d5wy8Lh9eFqtsvXl8Wtyvs5owETOtpd6yPBclo6JEpVJFobCSQjBD6m2uBGNMMEUNH06UcExLQ02NGK0FNYrMwO3Y23v3kXSIVduEWlsrO-1SqDAiiFDBGR_QbERr70Lw2lS9b1rpDwNU_fqrRn_V6G_gb47Vadtq9U__CSM_ir1tyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1030349656</pqid></control><display><type>article</type><title>Health and fertility in World Health Organization group 2 anovulatory women</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Baird, D. T. ; Balen, A. ; Escobar-Morreale, H. F. ; Evers, J. L. H. ; Fauser, B. C. J. M. ; Franks, S. ; Glasier, A. ; Homburg, R. ; La Vecchia, C. ; Devroey, P. ; Diedrich, K. ; Fraser, L. ; Gianaroli, L. ; Liebaers, I. ; Sunde, A. ; Tapanainen, J. S. ; Tarlatzis, B. ; Van Steirteghem, A. ; Veiga, A. ; Crosignani, P. G.</creator><creatorcontrib>Baird, D. T. ; Balen, A. ; Escobar-Morreale, H. F. ; Evers, J. L. H. ; Fauser, B. C. J. M. ; Franks, S. ; Glasier, A. ; Homburg, R. ; La Vecchia, C. ; Devroey, P. ; Diedrich, K. ; Fraser, L. ; Gianaroli, L. ; Liebaers, I. ; Sunde, A. ; Tapanainen, J. S. ; Tarlatzis, B. ; Van Steirteghem, A. ; Veiga, A. ; Crosignani, P. G. ; ESHRE Capri Workshop Group</creatorcontrib><description>Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation.
Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion.
Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results.
Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.</description><identifier>ISSN: 1355-4786</identifier><identifier>EISSN: 1460-2369</identifier><identifier>DOI: 10.1093/humupd/dms019</identifier><identifier>PMID: 22611175</identifier><language>eng</language><publisher>England</publisher><subject>Anovulation - classification ; Anovulation - complications ; Anovulation - diagnosis ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - surgery ; Clomiphene - therapeutic use ; Female ; Fertility ; Global Health ; Gonadotropins - therapeutic use ; Humans ; Infertility, Female - etiology ; Infertility, Female - surgery ; Infertility, Female - therapy ; Laparoscopy - adverse effects ; Laparoscopy - methods ; Obesity - complications ; Obesity - drug therapy ; Obesity - surgery ; Ovary - surgery ; Ovulation Induction - adverse effects ; Ovulation Induction - methods ; Polycystic Ovary Syndrome - etiology ; Polycystic Ovary Syndrome - surgery ; Polycystic Ovary Syndrome - therapy ; Pregnancy ; Risk Factors ; World Health Organization</subject><ispartof>Human reproduction update, 2012-09, Vol.18 (5), p.586-599</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-eeaeb52298549808dd77d1da995f3cb2d955595d4f6995436148f4fc054c94fd3</citedby><cites>FETCH-LOGICAL-c359t-eeaeb52298549808dd77d1da995f3cb2d955595d4f6995436148f4fc054c94fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22611175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baird, D. T.</creatorcontrib><creatorcontrib>Balen, A.</creatorcontrib><creatorcontrib>Escobar-Morreale, H. F.</creatorcontrib><creatorcontrib>Evers, J. L. H.</creatorcontrib><creatorcontrib>Fauser, B. C. J. M.</creatorcontrib><creatorcontrib>Franks, S.</creatorcontrib><creatorcontrib>Glasier, A.</creatorcontrib><creatorcontrib>Homburg, R.</creatorcontrib><creatorcontrib>La Vecchia, C.</creatorcontrib><creatorcontrib>Devroey, P.</creatorcontrib><creatorcontrib>Diedrich, K.</creatorcontrib><creatorcontrib>Fraser, L.</creatorcontrib><creatorcontrib>Gianaroli, L.</creatorcontrib><creatorcontrib>Liebaers, I.</creatorcontrib><creatorcontrib>Sunde, A.</creatorcontrib><creatorcontrib>Tapanainen, J. S.</creatorcontrib><creatorcontrib>Tarlatzis, B.</creatorcontrib><creatorcontrib>Van Steirteghem, A.</creatorcontrib><creatorcontrib>Veiga, A.</creatorcontrib><creatorcontrib>Crosignani, P. G.</creatorcontrib><creatorcontrib>ESHRE Capri Workshop Group</creatorcontrib><title>Health and fertility in World Health Organization group 2 anovulatory women</title><title>Human reproduction update</title><addtitle>Hum Reprod Update</addtitle><description>Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation.
Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion.
Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results.
Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.</description><subject>Anovulation - classification</subject><subject>Anovulation - complications</subject><subject>Anovulation - diagnosis</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - surgery</subject><subject>Clomiphene - therapeutic use</subject><subject>Female</subject><subject>Fertility</subject><subject>Global Health</subject><subject>Gonadotropins - therapeutic use</subject><subject>Humans</subject><subject>Infertility, Female - etiology</subject><subject>Infertility, Female - surgery</subject><subject>Infertility, Female - therapy</subject><subject>Laparoscopy - adverse effects</subject><subject>Laparoscopy - methods</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - surgery</subject><subject>Ovary - surgery</subject><subject>Ovulation Induction - adverse effects</subject><subject>Ovulation Induction - methods</subject><subject>Polycystic Ovary Syndrome - etiology</subject><subject>Polycystic Ovary Syndrome - surgery</subject><subject>Polycystic Ovary Syndrome - therapy</subject><subject>Pregnancy</subject><subject>Risk Factors</subject><subject>World Health Organization</subject><issn>1355-4786</issn><issn>1460-2369</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAURi0EoqUwsiKPLKF2_Eg8oopSRKUuIMbIje02yImDH6Dy6wlKYbpX9zv3Gw4A1xjdYSTIfJ_a1Ku5agPC4gRMMeUoywkXp8NOGMtoUfIJuAjhHSHMcVmcg0mec4xxwabgeaWljXsoOwWN9rGxTTzApoNvzlsFj-nG72TXfMvYuA7uvEs9zIcX95msjM4f4JdrdXcJzoy0QV8d5wy8Lh9eFqtsvXl8Wtyvs5owETOtpd6yPBclo6JEpVJFobCSQjBD6m2uBGNMMEUNH06UcExLQ02NGK0FNYrMwO3Y23v3kXSIVduEWlsrO-1SqDAiiFDBGR_QbERr70Lw2lS9b1rpDwNU_fqrRn_V6G_gb47Vadtq9U__CSM_ir1tyQ</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Baird, D. T.</creator><creator>Balen, A.</creator><creator>Escobar-Morreale, H. F.</creator><creator>Evers, J. L. H.</creator><creator>Fauser, B. C. J. M.</creator><creator>Franks, S.</creator><creator>Glasier, A.</creator><creator>Homburg, R.</creator><creator>La Vecchia, C.</creator><creator>Devroey, P.</creator><creator>Diedrich, K.</creator><creator>Fraser, L.</creator><creator>Gianaroli, L.</creator><creator>Liebaers, I.</creator><creator>Sunde, A.</creator><creator>Tapanainen, J. S.</creator><creator>Tarlatzis, B.</creator><creator>Van Steirteghem, A.</creator><creator>Veiga, A.</creator><creator>Crosignani, P. G.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Health and fertility in World Health Organization group 2 anovulatory women</title><author>Baird, D. T. ; Balen, A. ; Escobar-Morreale, H. F. ; Evers, J. L. H. ; Fauser, B. C. J. M. ; Franks, S. ; Glasier, A. ; Homburg, R. ; La Vecchia, C. ; Devroey, P. ; Diedrich, K. ; Fraser, L. ; Gianaroli, L. ; Liebaers, I. ; Sunde, A. ; Tapanainen, J. S. ; Tarlatzis, B. ; Van Steirteghem, A. ; Veiga, A. ; Crosignani, P. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-eeaeb52298549808dd77d1da995f3cb2d955595d4f6995436148f4fc054c94fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anovulation - classification</topic><topic>Anovulation - complications</topic><topic>Anovulation - diagnosis</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - surgery</topic><topic>Clomiphene - therapeutic use</topic><topic>Female</topic><topic>Fertility</topic><topic>Global Health</topic><topic>Gonadotropins - therapeutic use</topic><topic>Humans</topic><topic>Infertility, Female - etiology</topic><topic>Infertility, Female - surgery</topic><topic>Infertility, Female - therapy</topic><topic>Laparoscopy - adverse effects</topic><topic>Laparoscopy - methods</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - surgery</topic><topic>Ovary - surgery</topic><topic>Ovulation Induction - adverse effects</topic><topic>Ovulation Induction - methods</topic><topic>Polycystic Ovary Syndrome - etiology</topic><topic>Polycystic Ovary Syndrome - surgery</topic><topic>Polycystic Ovary Syndrome - therapy</topic><topic>Pregnancy</topic><topic>Risk Factors</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baird, D. T.</creatorcontrib><creatorcontrib>Balen, A.</creatorcontrib><creatorcontrib>Escobar-Morreale, H. F.</creatorcontrib><creatorcontrib>Evers, J. L. H.</creatorcontrib><creatorcontrib>Fauser, B. C. J. M.</creatorcontrib><creatorcontrib>Franks, S.</creatorcontrib><creatorcontrib>Glasier, A.</creatorcontrib><creatorcontrib>Homburg, R.</creatorcontrib><creatorcontrib>La Vecchia, C.</creatorcontrib><creatorcontrib>Devroey, P.</creatorcontrib><creatorcontrib>Diedrich, K.</creatorcontrib><creatorcontrib>Fraser, L.</creatorcontrib><creatorcontrib>Gianaroli, L.</creatorcontrib><creatorcontrib>Liebaers, I.</creatorcontrib><creatorcontrib>Sunde, A.</creatorcontrib><creatorcontrib>Tapanainen, J. S.</creatorcontrib><creatorcontrib>Tarlatzis, B.</creatorcontrib><creatorcontrib>Van Steirteghem, A.</creatorcontrib><creatorcontrib>Veiga, A.</creatorcontrib><creatorcontrib>Crosignani, P. G.</creatorcontrib><creatorcontrib>ESHRE Capri Workshop Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human reproduction update</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baird, D. T.</au><au>Balen, A.</au><au>Escobar-Morreale, H. F.</au><au>Evers, J. L. H.</au><au>Fauser, B. C. J. M.</au><au>Franks, S.</au><au>Glasier, A.</au><au>Homburg, R.</au><au>La Vecchia, C.</au><au>Devroey, P.</au><au>Diedrich, K.</au><au>Fraser, L.</au><au>Gianaroli, L.</au><au>Liebaers, I.</au><au>Sunde, A.</au><au>Tapanainen, J. S.</au><au>Tarlatzis, B.</au><au>Van Steirteghem, A.</au><au>Veiga, A.</au><au>Crosignani, P. G.</au><aucorp>ESHRE Capri Workshop Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health and fertility in World Health Organization group 2 anovulatory women</atitle><jtitle>Human reproduction update</jtitle><addtitle>Hum Reprod Update</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>18</volume><issue>5</issue><spage>586</spage><epage>599</epage><pages>586-599</pages><issn>1355-4786</issn><eissn>1460-2369</eissn><abstract>Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation.
Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion.
Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results.
Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.</abstract><cop>England</cop><pmid>22611175</pmid><doi>10.1093/humupd/dms019</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-4786 |
| ispartof | Human reproduction update, 2012-09, Vol.18 (5), p.586-599 |
| issn | 1355-4786 1460-2369 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1030349656 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Anovulation - classification Anovulation - complications Anovulation - diagnosis Cardiovascular Diseases - complications Cardiovascular Diseases - drug therapy Cardiovascular Diseases - surgery Clomiphene - therapeutic use Female Fertility Global Health Gonadotropins - therapeutic use Humans Infertility, Female - etiology Infertility, Female - surgery Infertility, Female - therapy Laparoscopy - adverse effects Laparoscopy - methods Obesity - complications Obesity - drug therapy Obesity - surgery Ovary - surgery Ovulation Induction - adverse effects Ovulation Induction - methods Polycystic Ovary Syndrome - etiology Polycystic Ovary Syndrome - surgery Polycystic Ovary Syndrome - therapy Pregnancy Risk Factors World Health Organization |
| title | Health and fertility in World Health Organization group 2 anovulatory women |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A02%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health%20and%20fertility%20in%20World%20Health%20Organization%20group%202%20anovulatory%20women&rft.jtitle=Human%20reproduction%20update&rft.au=Baird,%20D.%20T.&rft.aucorp=ESHRE%20Capri%20Workshop%20Group&rft.date=2012-09-01&rft.volume=18&rft.issue=5&rft.spage=586&rft.epage=599&rft.pages=586-599&rft.issn=1355-4786&rft.eissn=1460-2369&rft_id=info:doi/10.1093/humupd/dms019&rft_dat=%3Cproquest_cross%3E1030349656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1030349656&rft_id=info:pmid/22611175&rfr_iscdi=true |